A Phase III, multicenter, randomized, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as monotherapy and in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma

Trial Profile

A Phase III, multicenter, randomized, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as monotherapy and in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Renal cancer; Ureteral-neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms IMvigor 130; IMvigor130
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 20 Jun 2018 Planned End Date changed from 30 Jul 2020 to 17 Nov 2020.
    • 20 Jun 2018 Planned primary completion date changed from 31 Dec 2018 to 17 Nov 2020.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top